This is a randomized, placebo-controlled, double-blinded trial in which subjects with a post
concussive headache meeting inclusion criterion will be assigned to one of two treatment
groups: placebo or nortriptyline. Each group will be evaluated at week 0 and again each week
for the next 4 weeks of treatment with a concussion survey that rates their symptoms. At the
end of 4 weeks the study will be unblinded. It is hypothesized that the addition of
nortriptyline to the standard headache treatments will result in more rapid decrease of
symptom score than with placebo.